Atreca (BCEL)
(Delayed Data from OTC)
$0.09 USD
0.00 (-2.07%)
Updated May 21, 2024 09:30 AM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Atreca, Inc. [BCEL]
Reports for Purchase
Showing records 1 - 20 ( 159 total )
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ATRC-101 Discont., Focus Shifts to 444;Downgrading to NEUTRAL
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
ATRC-101 Out (For Good?) as Company Hits Reset; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b Interim Update at ASCO Demonstrates ATRC-101 Potential Across Advanced Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; ATRC-101 Data Update Expected at ASCO 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; ATRC-101 Stays the Course; ASCO Update Soon; Phase 2 Details by 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; ATRC-101''s Phase 1b Continues to Build a Solid Foundation for Possible Phase 2
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Title: Q4/FY22 Financials; ATRC-101 key readout in YE23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Productive Collaboration Allows CD3 Bispecific Program Against Solid Tumors to Take Shape; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ATRC-101 Clinical Update in Q1:23; Setback for EphA2 Program
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; ATRC-101 Clinical Update in 1Q23 a Key Value Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J